How Germany’s Standard of Care Influences Clinical Trial Participation with Martin Krauss

Meet Martin Krauss - the CEO of FGK Research, an expert in clinical research with a mission to advance medical treatments and improve patient outcomes. One year after their last episode together, Martin and Maya meet again to talk about the current challenges and developments in the clinical research landscape. Why is there a decline in biotechnology investments globally and how is that affecting the dynamics of the market? What are the challenges in implementing the Clinical Trial Information System (CTIS) in Europe? How is the new Medical Research Act in Germany going to increase efficiency and benefit patients?

  • (00:00) - Introduction of Martin Krauss
  • (01:43) - Challenges and Decline in Investments in Clinical Research
  • (03:24) - The Challenges and Improvements of the CTIS in Europe
  • (17:05) - The Impact of the Medical Research Act in Germany
  • (28:35) - Promoting Clinical Research and Raising Awareness
  • (33:16) - Making Clinical Trials More Efficient and Cost-Effective

Follow Maya Zlatanova: https://www.linkedin.com/in/mayazlatanova/
Follow Martin Krauss: https://www.linkedin.com/in/martin-krauss-460b489/ 
How Germany’s Standard of Care Influences Clinical Trial Participation with Martin Krauss
Broadcast by